Skip to main content

Deloitte Joins TranSMART Membership Program


Deloitte said this week that it is now a gold-level sponsor of the TranSMART Foundation and that as part of its sponsorship, Brett Davis, a principal with Deloitte Consulting and general manager of Deloitte Health Informatics, will join the foundation's board of directors.

The TranSMART Foundation launched its membership program last October to provide an ecosystem for partners that are developing, delivering, hosting, supporting and using its platform for translational research, and a sustainable way to achieve is objectives. The program offers three levels of sponsorship that confer a variety of benefits on partners.

The TranSMART open-source knowledge-management platform helps life-science and health-care organizations integrate phenotypic clinical data and molecular information to develop and refine hypotheses in their translational research and personalized medicine projects.

"Recombinant by Deloitte is one of the original developers of the TranSMART platform, and I am very pleased to see their continued involvement in the community," Keith Elliston, Ph.D., CEO of the tranSMART Foundation, said in a statement. Dan Housman, Deloitte Consulting's director and chief technology officer of Recombinant by Deloitte, added that his firm is "proud to have been involved in the original tranSMART platform" and remains committed to investing in its development.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.